IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

September 25th- Live from IMS 2026: Plenary session of the 23rd Annual Meeting of the International Myeloma Society

CME Congresses .

September 25th- Live from IMS 2026: Plenary session of the 23rd Annual Meeting of the International Myeloma Society

September 24th- Live from IMS 2026: Can the gut microbiome influence the efficacy and toxicity of CAR-T cells — and could we eventually manipulate it to improve patient outcomes?

CME Congresses .

September 24th- Live from IMS 2026: Can the gut microbiome influence the efficacy and toxicity of CAR-T cells — and could we eventually manipulate it to improve patient outcomes?

September 23rd- Live from IMS 2026: T-cell Engagers to Reorganize the Cytotoxic Immunological Synapse

CME Congresses .

September 23rd- Live from IMS 2026: T-cell Engagers to Reorganize the Cytotoxic Immunological Synapse

September 23rd- Live from IMS 2026: Rethinking First Relapse in Multiple Myeloma: CAR-T, Bispecifics, ADCs and the Challenge of Sequencing

CME Congresses .

September 23rd- Live from IMS 2026: Rethinking First Relapse in Multiple Myeloma: CAR-T, Bispecifics, ADCs and the Challenge of Sequencing

September 22nd- MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

CME Congresses .

September 22nd- MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

September 21st- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

CME Congresses .

September 21st- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

September 15th- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

CME Congresses .

September 15th- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

September 9th- Can three complementary mechanisms transform the treatment of one of the rarest and most aggressive hematologic malignancies?

CME Congresses .

September 9th- Can three complementary mechanisms transform the treatment of one of the rarest and most aggressive hematologic malignancies?

September 1st- Talquetamab at 3 Years: Durability, Safety, and the Future of Myeloma Sequencing

CME Congresses .

September 1st- Talquetamab at 3 Years: Durability, Safety, and the Future of Myeloma Sequencing

August 6th- Beyond the webinar- Preventing Relapse After Allogeneic Transplantation in High-Risk Myeloid Malignancies: Are We Entering the Era of Precision Post-Transplant Care?

CME Congresses .

August 6th- Beyond the webinar- Preventing Relapse After Allogeneic Transplantation in High-Risk Myeloid Malignancies: Are We Entering the Era of Precision Post-Transplant Care?